Korean Journal of Gastrointestinal Endoscopy 2007;34(6): 339-342.
크론병 환자에서 Infliximab 치료 후 발생한 결핵성 뇌수막염 1예
김연호·이범재·박종재·이원우·한우식·오성남·최도원·김재선·박영태·정희진*
고려대학교 의과대학 구로병원 소화기내과, *감염내과
Tuberculous Meningitis in a Patient with Crohn's Disease, Which was Treated with Infliximab
Youn Ho Kim, M.D., Beom Jae Lee, M.D., Jong-Jae Park, M.D., Won Woo Lee, M.D., Woo Sik Han, M.D., Sung Nam Oh, M.D., Do Won Choi, M.D., Jae Seon Kim, M.D., Young-Tae Bak, M.D. and Hee Jin Cheong, M.D.*
Department of Gastroenterology, *Infectious Department, Korea University Medical Center Guro Hospital, Seoul, Korea
Abstract
Clinical trials of tumor necrosis factor (TNF) inhibitor have demonstrated significant efficacy in those patients with Crohn's disease that is not responsive to other anti- inflammatory drug. Infliximab is a human-murine chimeric monoclonal antibody with a high binding affinity and specificity for TNF-α. Yet therapy with infliximab is associated with an increased risk of opportunistic infection, and especially tuberculosis. Here we reported on a case of tuberculous meningitis in 26-year-old man, and he was treated with infliximab for uncontrolled and fistulous Crohn's disease. We also include a review of the literature.
PDF Links
Full text via DOI 
Download Citation 
